Journal Mobile Options
Table of Contents
Vol. 64, No. 3, 2007
Issue release date: October 2007
Gynecol Obstet Invest 2007;64:134–137

Soluble HLA-G and Embryo Implantation: Frequently Asked Questions

Le Bouteiller P. · Tabiasco J. · Parinaud J.
aINSERM U563, Hôpital Purpan, Toulouse, and bLaboratoire de Biologie de la Reproduction, Hôpital Paule de Viguier, Toulouse, France

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Two major criteria are currently used for optimal human embryo selection in in vitro fertilization or intracytoplasmic sperm injection: overall morphology-based grading system and rate of fragmentation. The measurement of soluble HLA-G (sHLA-G) in human preimplantation embryo culture supernatants gives great hope that addition of such a biochemical quantitative criterion would further improve the rates of implantation. In this short review, we will examine the functional significance of this latter approach by discussing the following frequently asked questions: (1) Which sHLA-G isoform(s) might be present in the human preimplantation embryo culture supernatants? (2) Where do these sHLA-G molecules come from? (3) Why are some preimplantation embryos ‘HLA-G secretors’ and others not? (4) How might the functions exerted by sHLA-G molecules influence embryonic implantation?

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Fuzzi B, Rizzo R, Criscuoli L, Noci I, Melchiorri L, Scarselli B, Bencini E, Menicucci A, Baricordi OR: HLA-G expression in early embryos is a fundamental prerequisite for the obtainment of pregnancy. Eur J Immunol 2002;32:311–315.
  2. Sher G, Keskintepe L, Nouriani M, Roussev R, Batzofin J: Expression of sHLA-G in supernatants of individually cultured 46-h embryos: a potentially valuable indicator of ‘embryo competency’ and in vitro fertilization outcome. Reprod Biomed Online 2004;9:74–78.
  3. Noci I, Fuzzi B, Rizzo R, Melchiorri L, Criscuoli L, Dabizzi S, Biagiotti R, Pellegrini S, Menicucci A, Baricordi OR: Embryonic soluble HLA-G as a marker of developmental potential in embryos. Hum Reprod 2005;20:138–146.
  4. Sher G, Keskintepe L, Batzofin J, Fisch J, Acacio B, Ahlering P, Ginsburg M: Influence of early intracytoplasmic sperm injection-derived embryo sHLA-G expression on pregnancy and implantation rates: a prospective study. Hum Reprod 2005;20:1359–1363.
  5. Sher G, Keskintepe L, Fisch JD, Acacio BA, Ahlering P, Batzofin J, Ginsburg M: Soluble human leukocyte antigen G expression in phase I culture media at 46 hours after fertilization predicts pregnancy and implantation from day 3 embryo transfer. Fertil Steril 2005;83:1410–1413.
  6. Rebmann V, Lemaoult J, Rouas-Freiss N, Carosella ED, Grosse-Wilde H: Report of the Wet Workshop for Quantification of Soluble HLA-G, Essen 2004. Hum Immunol 2005;66:853–863.
  7. Noriko S, Hirotsugu H, Masanori Y, Takanori S, Motoko O, Katsuhiko H, Geraghty D, Ishitani A: Are in vitro fertilized eggs able to secrete soluble HLA-G? Am J Reprod Immunol 2004;52(suppl 1):P8.
  8. Van Lierop MJ, Wijnands F, Loke YW, Emmer PM, Lukassen HG, Braat DD, Van Der Meer A, Mosselman S, Joosten I: Detection of HLA-G by a specific sandwich ELISA using monoclonal antibodies G233 and 56B. Mol Hum Reprod 2002;8:776–784.
  9. Le Bouteiller P: Commentary: Major breakthrough in the HLA-G debate: occurrence of pregnancy in human depends on the HLA-G status of preimplantation embryos. Eur J Immunol 2002;32:309–310.
  10. Fujii T, Ishitani A, Geraghty DE: A soluble form of the HLA-G antigen is encoded by a messenger ribonucleic acid containing intron 4. J Immunol 1994;153:5516–5524.
  11. Park GM, Lee S, Park B, Kim E, Shin J, Cho K, Ahn K: Soluble HLA-G generated by proteolytic shedding inhibits NK-mediated cell lysis. Biochem Biophys Res Commun 2004;313:606–611.
  12. Lee DM, Lee TK, Song HB, Kim CH: The expression of matrix metalloproteinase-9 in human follicular fluid is associated with in vitro fertilisation pregnancy. BJOG 2005;112:946–951.
  13. Yao YQ, Barlow DH, Sargent IL: Differential expression of alternatively spliced transcripts of HLA-G in human preimplantation embryos and inner cell masses. J Immunol 2005;175:8379–8385.
  14. Solier C, Aguerre-Girr M, Lenfant F, Campan A, Berrebi A, Rebmann V, Grosse-Wilde H, Le Bouteiller P: Secretion of pro-apoptotic intron 4-retaining soluble HLA-G1 by human villous trophoblast. Eur J Immunol 2002;32:3576–3586.
  15. Morales P, Pace J, Platt J, Phillips T, Morgan K, Fazleabas A, Hunt J: Placental cell expression of HLA-G2 isoforms is limited to the invasive trophoblast phenotype. J Immunol 2003;171:6215–6224.
  16. Braude P, Bolton V, Moore S: Human gene expression first occurs between the four- and eight-cell stages of preimplantation development. Nature 1988;332:459–461.
  17. Jurisicova A, Casper RF, MacLusky NJ, Librach CL: Embryonic human leukocyte antigen-G expression: possible implications for human preimplantation development. Fertil Steril 1996;65:997–1002.
  18. Rebmann V, van der Ven K, Passler M, Pfeiffer K, Krebs D, Grosse-Wilde H: Association of soluble HLA-G plasma levels with HLA-G alleles. Tissue Antigens 2001;57:15–21.
  19. Tan Z, Shon AM, Ober C: Evidence of balancing selection at the HLA-G promoter region. Hum Mol Genet 2005;14:3619–3628.
  20. Hviid TV, Rizzo R, Melchiorri L, Stignani M, Baricordi OR: Polymorphism in the 5′ upstream regulatory and 3′ untranslated regions of the HLA-G gene in relation to soluble HLA-G and IL-10 expression. Hum Immunol 2006;67:53–62.
  21. Pfeiffer KA, Fimmers R, Engels G, van der Ven H, van der Ven K: The HLA-G genotype is potentially associated with idiopathic recurrent spontaneous abortion. Mol Hum Reprod 2001;7:373–378.
  22. Brownell MS, Warner CM: Ped gene expression by embryos cultured in vitro. Biol Reprod 1988;39:806–811.
  23. Yie SM, Balakier H, Motamedi G, Librach CL: Secretion of human leukocyte antigen-G by human embryos is associated with a higher in vitro fertilization pregnancy rate. Fertil Steril 2005;83:30–36.
  24. Chaouat G, Ledee-Bataille N, Chea KB, Dubanchet S: Cytokines and implantation. Chem Immunol Allergy 2005;88:34–63.
  25. Le Bouteiller P, Legrand-Abravanel F, Solier C: Soluble HLA-G1 at the materno-foetal interface – a review. Placenta 2003;24(suppl A):S10–S15.
  26. Hunt JS, Petroff MG, McIntire RH, Ober C: HLA-G and immune tolerance in pregnancy. FASEB J 2005;19:681–693.
  27. Tabiasco J, Rabot M, Aguerre-Girr M, El Costa H, Berrebi A, Parant O, Laskarin G, Juretic K, Bensussan A, Rukavina D, Le Bouteiller P: Human decidual NK cells: unique phenotype and functional properties – a review. Placenta 2006;27(suppl A):34–39.

    External Resources

  28. Piccinni MP, Beloni L, Livi C, Maggi E, Scarselli G, Romagnani S: Defective production of both leukemia inhibitory factor and type 2 T-helper cytokines by decidual T cells in unexplained recurrent abortions. Nat Med 1998;4:1020–1024.
  29. Piccinni MP, Scaletti C, Mavilia C, Lazzeri E, Romagnani P, Natali I, Pellegrini S, Livi C, Romagnani S, Maggi E: Production of IL-4 and leukemia inhibitory factor by T cells of the cumulus oophorus: a favorable microenvironment for pre-implantation embryo development. Eur J Immunol 2001;31:2431–2437.
  30. Fournel S, Aguerre-Girr M, Huc X, Lenfant F, Alam A, Toubert A, Bensussan A, Le Bouteiller P: Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J Immunol 2000;164:6100–6104.
  31. Rajagopalan S, Bryceson YT, Kuppusamy SP, Geraghty DE, Meer AV, Joosten I, Long EO: Activation of NK cells by an endocytosed receptor for soluble HLA-G. PLoS Biol 2005;4:e9.
  32. Shiroishi M, Kuroki K, Ose T, Rasubala L, Shiratori I, Arase H, Tsumoto K, Kumagai I, Kohda D, Maenaka K: Efficient leukocyte Ig-like receptor signaling and crystal structure of disulfide-linked HLA-G dimer. J Biol Chem 2006;281:10439–10447.
  33. Fons P, Chabot S, Cartwright JE, Lenfant F, L’Faqihi F, Giustiniani J, Herault JP, Gueguen G, Bono F, Savi P, Aguerre-Girr M, Fournel S, Malecaze F, Bensussan A, Plouët J, Le Bouteiller P: Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. Blood 2006;108:2608–2615 (doi: 10.1182/blood-2005-12-019919).
  34. Boyson JE, Erskine R, Whitman MC, Chiu M, Lau JM, Koopman LA, Valter MM, Angelisova P, Horejsi V, Strominger JL: Disulfide bond-mediated dimerization of HLA-G on the cell surface. Proc Natl Acad Sci USA 2002;99:16180–16185.

Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00